文章：

胸腺肿瘤新辅助疗法的再审视：一条漫长而曲折的道路

A Re-Examination of Neoadjuvant Therapy for Thymic Tumors: A Long and Winding Road

原文发布日期：26 April 2024

DOI: 10.3390/cancers16091680

类型: Article

开放获取: 是

英文摘要：

For most patients with advanced thymic epithelial tumors (TETs), a complete resection is a strong indicator of a better prognosis. But sometimes, primary surgery is unsatisfactory, and preoperative therapy is needed to facilitate complete resection. Neoadjuvant chemotherapy is the most used form of preoperative therapy. But studies on neoadjuvant chemotherapy have included mainly patients with thymoma; its efficacy in patients with thymic carcinoma is less known. Neoadjuvant chemoradiation has also been explored in a few studies. Novel therapies such as immunotherapy and targeted therapy have shown efficacy in patients with recurrent/metastatic TETs as a second-line option; their role as preoperative therapy is still under investigation. In this review, we discuss the existing evidence on preoperative therapy and the insight it provides for current clinical practice and future studies.

摘要翻译： 

对于大多数晚期胸腺上皮肿瘤（TETs）患者而言，完全切除是预后良好的重要指标。然而，原发性手术有时难以达到理想效果，此时需通过术前治疗以实现完全切除。新辅助化疗是目前最常用的术前治疗方式，但相关研究主要集中于胸腺瘤患者，其在胸腺癌患者中的疗效尚不明确。少数研究亦探讨了新辅助放化疗的应用。新型疗法如免疫治疗和靶向治疗，在复发/转移性TETs的二线治疗中已显示出疗效，但其作为术前治疗的价值仍有待进一步研究。本文综述了术前治疗的现有证据，并探讨其对当前临床实践及未来研究的启示。

原文链接：

A Re-Examination of Neoadjuvant Therapy for Thymic Tumors: A Long and Winding Road